Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials
Abstract
OBJECTIVE: To evaluate the effect of pregestational metformin administration on abortion risk in polycystic ovary syndrome (PCOS) patients.
DESIGN: Systematic review and meta-analysis.
SETTING: Academic Department of Obstetrics and Gynecology in Italy.
PATIENT(S): Women affected by PCOS receiving pregestational metformin.
INTERVENTION(S): Systematic review of randomized controlled trials (RCTs) published up to June 2008 and subsequent meta-analysis.
MAIN OUTCOME MEASURE(S): Abortion rate.
RESULT(S): Seventeen RCTs were included in the final analysis. Overall, no effect of the metformin administration was detected on the abortion risk. No statistically significant effect of metformin on the abortion risk was observed in any comparison when subgrouping the RCTs according to received treatment.
CONCLUSION(S): Metformin has no effect on the abortion risk in PCOS patients when administered before pregnancy.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.